{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Columbus&page=20&state=Ohio", "query": { "state": "Ohio", "city": "Columbus", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 10845, "total_pages": 1085, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Columbus&page=21&state=Ohio&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Columbus&page=19&state=Ohio&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T07:04:41.809Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04068103", "title": "Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Colon Adenocarcinoma", "Stage IIA Colon Cancer AJCC v8" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Patient Observation", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 635, "start_date": "2019-12-16", "completion_date": "2026-06-21", "has_results": true, "last_update_posted_date": "2025-05-07", "last_synced_at": "2026-11-02T07:04:41.809Z", "location_count": 932, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 639 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04068103" }, { "nct_id": "NCT00729586", "title": "Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Carcinoma", "Recurrent Uterine Corpus Carcinoma", "Stage IIIA Uterine Corpus Cancer", "Stage IIIB Uterine Corpus Cancer", "Stage IIIC1 Uterine Corpus Cancer", "Stage IIIC2 Uterine Corpus Cancer", "Stage IVA Uterine Corpus Cancer", "Stage IVB Uterine Corpus Cancer" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Megestrol Acetate", "type": "DRUG" }, { "name": "Tamoxifen Citrate", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 73, "start_date": "2008-09", "completion_date": "2017-02", "has_results": true, "last_update_posted_date": "2019-07-23", "last_synced_at": "2026-11-02T07:04:41.809Z", "location_count": 108, "location_summary": "Burbank, California • Palo Alto, California • San Diego, California + 75 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00729586" }, { "nct_id": "NCT01791127", "title": "Safety and Performance Study of the Siello S Pacing Lead", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Safety and Effectiveness of the Siello S Lead" ], "interventions": [ { "name": "market-released BIOTRONIK pacemaker system including one or two Siello S leads.", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Biotronik, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1758, "start_date": "2013-03-13", "completion_date": "2019-04-17", "has_results": true, "last_update_posted_date": "2020-06-01", "last_synced_at": "2026-11-02T07:04:41.809Z", "location_count": 53, "location_summary": "La Jolla, California • La Mesa, California • New Haven, Connecticut + 50 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Stamford", "state": "Connecticut" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01791127" }, { "nct_id": "NCT05102370", "title": "A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clonal Cytopenia of Undetermined Significance", "CCUS Clonal Cytopenia of Undetermined Significance" ], "interventions": [ { "name": "Enasidenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2021-10-06", "completion_date": "2026-01-26", "has_results": false, "last_update_posted_date": "2026-01-27", "last_synced_at": "2026-11-02T07:04:41.809Z", "location_count": 12, "location_summary": "Rochester, Minnesota • St Louis, Missouri • Basking Ridge, New Jersey + 9 more", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05102370" }, { "nct_id": "NCT05250973", "title": "A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Amyloidosis" ], "interventions": [ { "name": "Daratumumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 151, "start_date": "2022-03-01", "completion_date": "2026-11-23", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-11-02T07:04:41.809Z", "location_count": 16, "location_summary": "Duarte, California • New Haven, Connecticut • Tampa, Florida + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05250973" }, { "nct_id": "NCT04697069", "title": "A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acneiform Eruptions" ], "interventions": [ { "name": "Imsidolimab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Vanda Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 4, "start_date": "2021-05-04", "completion_date": "2021-12-13", "has_results": true, "last_update_posted_date": "2025-09-22", "last_synced_at": "2026-11-02T07:04:41.809Z", "location_count": 5, "location_summary": "Tampa, Florida • Boston, Massachusetts • St Louis, Missouri + 2 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04697069" }, { "nct_id": "NCT01283594", "title": "Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Parkinson's Disease" ], "interventions": [ { "name": "Tozadenant (SYN115) 60 mg BID", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Levodopa (L-dopa)", "type": "DRUG" }, { "name": "Tozadenant (SYN115) 120 mg BID", "type": "DRUG" }, { "name": "Tozadenant (SYN115) 180 mg BID", "type": "DRUG" }, { "name": "Tozadenant (SYN115) 240 mg BID", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biotie Therapies Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "30 Years to 80 Years" }, "enrollment_count": 420, "start_date": "2011-03", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2019-01-17", "last_synced_at": "2026-11-02T07:04:41.809Z", "location_count": 40, "location_summary": "Birmingham, Alabama • La Jolla, California • Loma Linda, California + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oxnard", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01283594" }, { "nct_id": "NCT04387656", "title": "NCI COVID-19 in Cancer Patients, NCCAPS Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "COVID-19 Infection", "Hematopoietic and Lymphatic System Neoplasm", "Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Data Collection", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1877, "start_date": "2020-06-05", "completion_date": "2027-10-14", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-11-02T07:04:41.809Z", "location_count": 928, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 589 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04387656" }, { "nct_id": "NCT04614337", "title": "Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Growth Hormone Deficiency" ], "interventions": [ { "name": "LUM-201", "type": "DRUG" }, { "name": "rhGH Norditropin® pen (34 µg/kg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lumos Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "12 Years", "sex": "ALL", "summary": "3 Years to 12 Years" }, "enrollment_count": 104, "start_date": "2020-12-31", "completion_date": "2024-09-04", "has_results": true, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-11-02T07:04:41.809Z", "location_count": 27, "location_summary": "Sacramento, California • San Diego, California • Greenwood Village, Colorado + 24 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Greenwood Village", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04614337" }, { "nct_id": "NCT00376961", "title": "S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 68, "start_date": "2006-08", "completion_date": "2017-09", "has_results": true, "last_update_posted_date": "2017-11-06", "last_synced_at": "2026-11-02T07:04:41.809Z", "location_count": 147, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 95 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Burbank", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00376961" } ] }